docetaxel + epirubicin + trastuzumab

This is a combination therapy regimen consisting of docetaxel (a taxane chemotherapy), epirubicin (an anthracycline chemotherapy), and trastuzumab (a HER2-targeted monoclonal antibody). The regimen is typically administered in a sequential manner, with epirubicin/cyclophosphamide followed by docetaxel and trastuzumab. This combination is used primarily in the neoadjuvant setting for HER2-positive breast cancer to reduce tumor size before surgery. The mechanism involves multiple pathways: docetaxel disrupts microtubule function, epirubicin intercalates DNA and inhibits topoisomerase II, while trastuzumab targets the HER2 receptor to block signaling pathways that promote cancer cell growth.